Private healthcare in 2026: record admissions, real headwinds

In late May I attended the LaingBuisson Private Healthcare Summit, one of the sector’s longest-running gatherings of providers, insurers, investors and advisors. The data presented confirmed a market performing at record levels. What the day also made clear is that volume growth alone is not the story. The more instructive questions are about who is driving that growth, where the pressure points are, and what the sector needs to do next.

The numbers are strong, but unevenly distributed

Private admissions have reached their highest ever level. Healthcode processed over one million invoices per month for each of the last four months of 2024 and is on track to repeat that for five months this year. The PHIN data covering Q1 2022 to Q2 2025 recorded around 273,000 cancer admissions alone over three years, with chemotherapy accounting for 64% of those. Across the market more broadly, insured demand remains the primary driver of admitted care growth, with early signals from Q1 2026 Healthcode data suggesting that trajectory continuing.

But the distribution matters. Chemotherapy admissions rose 10% year on year. Cardiac ablation was up 20%. Cholecystectomy rose 13%, and varicose vein sclerotherapy by 32%. Set against that, knee replacements declined 9%, tonsillectomies fell 16%, and gastrectomy dropped 72%. The market is not rising uniformly. It is reconfiguring around specific clinical areas. The winners and losers within that shift are not always the ones the sector was expecting, and providers whose capacity planning still reflects the pre-pandemic mix are planning against the wrong baseline.

A changing patient

There was an honest and at times candid conversation about who is now choosing private care. Younger patients are entering the market. The 40 to 49 age group showed the most significant volume increase, with an additional 1,400 admissions. Dissatisfaction with NHS access, a sense of disconnection from the system, and an ‘on demand’ cultural shift are all contributing.

The more striking observation, though, was about perception. Most people believe private healthcare is materially more expensive than it actually is. That gap between what people assume and what they would actually pay is not a niche communications problem. It is one of the sector’s most significant structural barriers to growth. There is more work to do in educating consumers about what is genuinely accessible and at what price point, and the employers increasingly funding access to care for their staff have a role to play in closing that gap.

The digitisation of access is accelerating in parallel. Doctify reported a fivefold increase in clinicians offering online booking since 2021, reaching around 8,000 clinicians by early 2026. Younger patients expect this as a baseline, not a differentiator. Providers who have not invested in digital access are not competing on a different level of service, they are simply not visible to a growing segment of the market.

Cancer care: the case for better integration

Breast cancer remains the largest tumour group in the private sector, and the volume data reflects a market that is taking cancer care seriously. Chemotherapy admissions rose 10% year on year, and the PHIN data covering Q1 2022 to Q2 2025 shows London recording the largest absolute growth in cancer admissions of any region, up 5,385 over the period.

But volume growth should not be mistaken for a well-functioning pathway. The structural problem the day kept returning to is fragmentation. Private cancer care and NHS cancer care do not integrate well. Insurers fund up to a point, but the handover back to NHS care is poorly managed in many cases. The consequences are clinical as well as financial: patients who might benefit from continuity are instead navigating a boundary between two systems that do not communicate, and the human cost of that gap is real.

From an employer perspective, this matters in a direct and measurable way. Patients diagnosed with stage 3 or 4 cancer who face delays or disjointed pathways are far less likely to return to work. That is one reason why employer interest in earlier detection and funded screening is growing, and why the ROI case for insurer-funded cancer screening programmes is becoming harder to dismiss. The economics of earlier diagnosis are compelling: better outcomes, lower treatment costs, and a meaningfully higher chance that a patient returns to productive working life.

The operating environment remains uncertain

Record admissions figures should not obscure the pressures that are building for providers. Ophthalmology is the clearest current example. A 19% tariff reduction on basic cataract procedures, combined with ongoing volume, is creating genuine financial stress for providers in that specialty. The ripple effects into adjacent elective areas have not yet been fully modelled.

More broadly, there is a pattern worth naming. In parts of the market, prices are being set based on what commissioners would like to pay rather than what can be realistically delivered. That creates specific risk for providers considering investment in new service lines. NHS-funded work in independent hospitals, which historically provided a degree of floor-level revenue stability, is not the anchor it was. The diagnostic procurement market tells that story plainly: where five years ago there were four or five serious bidders for a contract, there are now more than 50. The market has grown significantly, but so has the competition and the downward pressure on margins that comes with it.

What needs to happen next

A few things stood out as genuinely unresolved by the end of the day.

1. First, the affordability perception problem requires a more concerted response. The sector cannot rely on organic word-of-mouth to correct what is a widely-held misconception about cost. Insurers, providers and employers need to work together on a clearer consumer narrative.
2. Second, interoperability between NHS and private sector systems remains a genuine gap. Understanding the patient journey end to end, being honest about where the handover points fail, and investing in systems that actually communicate are not aspirational goals. They are prerequisites for delivering the quality of care the sector says it is committed to.
3. Third, pricing discipline matters. A market in which investment decisions are made against unrealistic revenue assumptions is a market that generates value destruction, not value creation. The sector has the data to price rationally. The question is whether it has the collective resolve to do so consistently.

The demand is real, and the structural drivers behind it are not going away. But sustaining this growth will require the private sector to be more joined-up on patient pathways, more transparent on affordability, and more rigorous about where its economic model is under stress.

In summary

The private healthcare market enters 2025 in a position of genuine strength, but one that carries structural questions it has not yet answered. Admissions are at record highs, insured demand is growing, and a younger, more digitally-native patient population is entering the market. The sector has real momentum.

What it does not yet have is the integration, the pricing discipline, or the consumer communication infrastructure to convert that momentum into durable long-term growth. The NHS handover problem remains unsolved. The affordability perception gap remains wide. And in specific clinical areas, notably ophthalmology but not only there, the financial model is under pressure in ways that will require deliberate responses rather than incremental adjustment.

The private sector’s relationship with the NHS is also at an inflection point. As NHS-funded volumes in independent hospitals soften and commissioning assumptions shift, providers who built their business models around that floor need to be rebuilding them around something more resilient.